Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 6/20 | 0.56 |
| ▸ | MAOB | P27338 | 5/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | CETP | P11597 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1615288 | 0.87 | APP (0.57) | APPMAOBKDM4EALDH1A1GAA | |
| SCHEMBL1508054 | 0.84 | APP (0.63) | APPMAOBKDM4EALDH1A1HPGD | |
| SCHEMBL1615447 | 0.80 | APP (0.55) | APPMAOBKDM4EALDH1A1GAA | |
| SCHEMBL1615320 | 0.76 | APP (0.63) | APPMAOBKDM4EALDH1A1HPGD | |
| SCHEMBL1615516 | 0.74 | APP (0.56) | APPMAOBKDM4EALDH1A1GAA | |
| SCHEMBL13351692 | 0.73 | MAOB (0.70) | APPMAOBKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL1508001 | 0.72 | APP (1.00) | APPMAOB | |
| SCHEMBL13351693 | 0.71 | APP (0.63) | APPMAOBKDM4EALDH1A1HPGD | |
| SCHEMBL14693781 | 0.71 | MAOB (0.76) | APPMAOBKDM4EALDH1A1GAA | |
| SCHEMBL1508064 | 0.70 | APP (0.66) | APPMAOBKDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2300481-B1 | NOVEL SUBSTITUTED AZABENZOXAZOLES | MERCK SHARP & DOHME (US) | 2015-09-30 | — | — | EP | claimed |
| US-8530483-B2 | Substituted azabenzoxazoles | MERCK SHARP & DOHME CORP. (US) | 2013-09-10 | — | — | US | claimed |
| US-20110085985-A1 | NOVEL SUBSTITUTED AZABENZOXAZOLES | MERCK SHARP & DOHME LLC | 2011-04-14 | — | — | US | claimed |
| EP-2300481-B1 | NOVEL SUBSTITUTED AZABENZOXAZOLES | MERCK SHARP & DOHME (US) | 2015-09-30 | — | — | EP | disclosed |
| EP-2300481-B1 | NOVEL SUBSTITUTED AZABENZOXAZOLES | MERCK SHARP & DOHME (US) | 2015-09-30 | — | — | EP | disclosed |
| US-8530483-B2 | Substituted azabenzoxazoles | MERCK SHARP & DOHME CORP. (US) | 2013-09-10 | — | — | US | disclosed |
| US-8530483-B2 | Substituted azabenzoxazoles | MERCK SHARP & DOHME CORP. (US) | 2013-09-10 | — | — | US | disclosed |
| US-8530483-B2 | Substituted azabenzoxazoles | MERCK SHARP & DOHME CORP. (US) | 2013-09-10 | — | — | US | disclosed |
| US-20110212031-A1 | NOVEL SUBSTITUTED AZABENZOXAZOLES | MERCK SHARP & DOHME CORP. | 2011-09-01 | — | — | US | disclosed |
| US-20110212031-A1 | NOVEL SUBSTITUTED AZABENZOXAZOLES | MERCK SHARP & DOHME CORP. | 2011-09-01 | — | — | US | disclosed |
| US-20110212031-A1 | NOVEL SUBSTITUTED AZABENZOXAZOLES | MERCK SHARP & DOHME CORP. | 2011-09-01 | — | — | US | disclosed |
| US-20110085985-A1 | NOVEL SUBSTITUTED AZABENZOXAZOLES | MERCK SHARP & DOHME LLC | 2011-04-14 | — | — | US | disclosed |
| US-20110085985-A1 | NOVEL SUBSTITUTED AZABENZOXAZOLES | MERCK SHARP & DOHME LLC | 2011-04-14 | — | — | US | disclosed |
| US-20110085985-A1 | NOVEL SUBSTITUTED AZABENZOXAZOLES | MERCK SHARP & DOHME LLC | 2011-04-14 | — | — | US | disclosed |
| WO-2010051196-A1 | NOVEL SUBSTITUTED AZABENZOXAZOLES | MERCK SHARP & DOHME CORP. (US) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110085985-A1 | NOVEL SUBSTITUTED AZABENZOXAZOLES | APBA1, APP, BACE1 | APP 2/4885MAOB 21/4885KDM4E 182/4885 |
| US-20110212031-A1 | NOVEL SUBSTITUTED AZABENZOXAZOLES | MAOB, MAOA, AANAT | APP 73/4885MAOB 1/4885KDM4E 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.